A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : beta2GPI / beta2-glycoprotein I

[Related PubMed/MEDLINE]
Total Number of Papers: 457
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   beta2GPI  (>> Co-occurring Abbreviation)
Long Form:   beta2-glycoprotein I
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Anti-β2-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action. FV, FXa, LA
2021 In vivo evidence of angiogenesis inhibition by β2-glycoprotein I subfractions in the chorioallantoic membrane of chicken embryos. CAM
2021 Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. APS
2021 β2 glycoprotein I participates in phagocytosis of apoptotic neurons and in vascular injury in experimental brain stroke. aPL, ihBMEC, tMCAO
2020 Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. aPL, APS, aTMA, LN, SLE
2020 Anti-domain 1 beta2 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro. aCL, aPL, LA, MFI, PBMCs
2020 Antiphospholipid antibodies and extracellular vesicles in pregnancy. aPL, EVs
2020 Apolipoprotein H drives hepatitis B surface antigen retention and endoplasmic reticulum stress during hepatitis B virus infection. apo H, BiP, CHOP, ER, HBsAg, HBV, XBP1
2020 Beta2 glycoprotein I-derived therapeutic peptides induce sFlt-1 secretion to reduce melanoma vascularity and growth. ---
10  2020 Complement Activation and Thrombin Generation by MBL Bound to β2-Glycoprotein I. APS, MBL
11  2020 Distinct and overlapping effects of β2-glycoprotein I conformational variants in ligand interactions and functional assays. ---
12  2020 In silico identification of new inhibitors for βeta-2-glycoprotein I as a major antigen in antiphospholipid antibody syndrome. APS, MD
13  2020 Rapid and specific detection of oxidized LDL/beta2GPI complexes via facile lateral flow immunoassay. GNP, LFIA, oxLDL
14  2020 Soluble vascular biomarkers in rheumatoid arthritis and ankylosing spondylitis: effects of one-year anti-TNF-α therapy. anti-Hsp60, AS, BNP, CV, CZP, ETN, FMD, IMT, oxLDL, PWV, RA, suPAR, TNF-alpha
15  2020 T Cell Proliferative Responses and IgG Antibodies to β2GPI in Patients with Diabetes and Atherosclerosis. MI
16  2020 The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. aPLs, APS, DI, DV
17  2020 The role of thrombospondin-1 in the pathogenesis of antiphospholipid syndrome. APS, HD, HUVECs, LA, SLE, TSP-1
18  2019 Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome. aPL, HMGB1, SLE, sRAGE
19  2019 Anti-β2GPI/β2GPI induces human neutrophils to generate NETs by relying on ROS. ERK, NETs, PMA, ROS
20  2019 Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity. HSP, oxLDL
21  2019 beta2-Glycoprotein I-Reactive T Cells in Autoimmune Disease. aPL, APS, MHC, SLE, Th
22  2019 Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. APS, ITP, MBB2, PAPS, SLE
23  2019 Induction of tissue factor expression by anti-beta2-glycoprotein I is mediated by tumor necrosis factor alpha. aPL, TF, TNF-alpha
24  2019 Mutants of beta2-glycoprotein I: Their features and potent applications. DI, PE, PL
25  2019 News and meta-analysis regarding anti-Beta 2 glycoprotein I antibodies and their determination. APS
26  2019 Pathogenic Autoreactive T and B Cells Cross-React with Mimotopes Expressed by a Common Human Gut Commensal to Trigger Autoimmunity. APS, R.int
27  2019 Platelet Activation by Antiphospholipid Antibodies Depends on Epitope Specificity and is Prevented by mTOR Inhibitors. aPL, APS, IgG, mTOR
28  2019 Post-translational modifications of proteins in antiphospholipid antibody syndrome. aPLs, PTMs
29  2019 Role of TLR‑4 in anti‑beta2‑glycoprotein I‑induced activation of peritoneal macrophages and vascular endothelial cells in mice. aPL, APS, IL, LPS, MAPK, VECs
30  2019 The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. APS
31  2018 Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. abeta2GPI, aCL, aD1, aD4-5, aPG, aPL, APS, AUC, HS, LIA, SARD
32  2018 Anticardiolipin (aCL) in sera from periodontitis subjects activate Toll-like receptor 4 (TLR4). aCL, aCL, APS, HEK, TLR's, TLR4
33  2018 Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome. APS
34  2018 Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. aPLs, APS, IgG, PDI, PS, TF
35  2018 Diminished expression of beta2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. CAC, ITP, JNK
36  2018 Effects of anti-beta2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity. APS
37  2018 Effects of Toll-like receptor 4 on beta2-glycoprotein I-induced splenic T cell subsets differentiation. BMDCs, DCs, NS, TLR4
38  2018 HBsAg/beta2GPI activates the NF‑kappaB pathway via the TLR4/MyD88/IkappaBalpha axis in hepatocellular carcinoma. HBV, HCC, MyD88, NF, rSHB, TLR4
39  2018 Lysine residues control the conformational dynamics of beta 2-glycoprotein I. APS, OPA
40  2018 Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases? APS
41  2018 Oxidative post-translational modification of betaeta 2-glycoprotein I in the pathophysiology of the anti-phospholipid syndrome. aPL, APS
42  2018 PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. aPL, APS, DI, PEG-DI
43  2018 Predictive Value of Oxidized Low-Density Lipoprotein/beta2-Glycoprotein-I Complexes (oxLDL/beta2GPI) in Nonautoimmune Atherothrombosis. ARE, M/F, MI, OR, oxLDL, VTE
44  2018 Pro‑atherogenic activation of A7r5 cells induced by the oxLDL/beta2GPI/anti‑beta2GPI complex. oxLDL, TLR4
45  2018 Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study. APA, ITP, LA
46  2018 The clinical value of assays detecting antibodies against domain I of beta2-glycoprotein I in the antiphospholipid syndrome. aPLs, APS, CIA, DI, G40-R43
47  2018 The interaction of beta2-glycoprotein I with lysophosphatidic acid in platelet aggregation and blood clotting. LDL, LPA
48  2018 Thrombophilia Caused by Beta2-Glycoprotein I Deficiency: In Vitro Study of a Rare Mutation in APOH Gene. apo H, AT, LA, PC, PS, TM
49  2018 Tolerogenic beta2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome. APAs, aPTTs, IL
50  2017 A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome. APL, APS
51  2017 Antigenicity analysis of human parvovirus B19-VP1u protein in the induction of anti-phospholipid syndrome. APS, CL, sPLA2, tVP1u, VP1u
52  2017 Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. aPL, DI, I/R, MI
53  2017 beta2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome. APS
54  2017 Betaeta 2-glycoprotein I protects mice against gram-negative septicaemia in a sexually dimorphic manner. CFU, E. coli, LPS, WT
55  2017 Cellular immune response to beta2-glycoprotein-I valine/leucine247 phenotypes in Mexican patients with primary antiphospholipid syndrome. DSC, HC, PAPS
56  2017 Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops. PMA
57  2017 Effects of reduced beta2 glycoprotein I on high glucose‑induced cell death in HUVECs. DM, HUVECs, NO, PTEN
58  2017 Mechanisms of Cellular Activation in the Antiphospholipid Syndrome. ANXA2, aPL, LRP8, TLR4
59  2017 Oxidation of β2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. anti-CL, aPL, APS, DI
60  2017 Reduced beta 2 glycoprotein I prevents high glucose-induced cell death in HUVECs through miR-21/PTEN. DM, HUVECs, PTEN, Rbeta2GPI
61  2017 Relationship Between Fetal Loss and Serum Gonadal Hormones Level in Experimental Antiphospholipid Syndrome Mouse. ---
62  2017 Solid Phase Immunoassay for the Detection of Anti-beta2 Glycoprotein I Antibodies. APS
63  2017 The purification of reduced beta2-glycoprotein I showed its native activity in vitro. DTT, HUVECs, IL-10, LPS, MCP-1, TNF-alpha, Trx-1
64  2017 The role of platelets in antiphospholipid syndrome. APS, GPIbalpha, PF4
65  2017 The Significance of Antibodies against Domain I of Beta-2 Glycoprotein I in Antiphospholipid Syndrome. aPLs, APS
66  2016 A potent multivalent vaccine for modulation of immune system in atherosclerosis: an in silico approach. HSP60
67  2016 Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools. aPL, APS, DI
68  2016 Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. aPL, APS, CL, humoAbs, IDC, LIA, PL, VDRL
69  2016 Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of Toll-like receptor 8. aPL, APOs, APS, DN, IL, miRs, SLE, TLR4
70  2016 Beta2-glycoprotein I Expression in Lupus Nephritis Patients with Antiphospholipid-associated Nephropathy. aPL, aPLN, LN
71  2016 beta2-Glycoprotein I Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis by Suppressing the Phosphorylation of Extracellular Signal-Regulated Kinase 1/2, Akt, and Endothelial Nitric Oxide Synthase. BrdU, eNOS, VEGF
72  2016 Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome. ANXA2, APS, AU, eAPS, ELISA, IgG
73  2016 C‑reactive protein/oxidized low density lipoprotein/beta2‑glycoproteini complexes induce lipid accumulation and inflammatory reaction in macrophages via p38/mitogen‑activated protein kinase and nuclear factor‑kappaB signaling pathways. CRP, IL, NF, oxLDL
74  2016 Gram Negative Bacterial Inflammation Ameliorated by the Plasma Protein Beta 2-Glycoprotein I. LPS
75  2016 Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis. aPL, ApoER2, APS, eNOS, mAb
76  2016 In vivo distribution of single chain variable fragment (scFv) against atherothrombotic oxidized LDL/beta2-glycoprotein I complexes into atherosclerotic plaques of WHHL rabbits: Implication for clinical PET imaging. APS, oxLDL, scFv, WHHL
77  2016 Inverted erythrocyte membranes demonstrate beta2GPI-antiphospholipid antibody interactions and membrane crosslinking. APS, iEMs, PS
78  2016 Molecular mapping of alpha-thrombin (alphaT)/beta2-glycoprotein I (beta2GpI) interaction reveals how beta2GpI affects alphaT functions. alpha-T, PC
79  2016 Oxidized Low-Density Lipoprotein-beta2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. oxLDL
80  2016 OxLDL/beta2-glycoprotein I complex as a pro-atherogenic autoantigen. Is atherosclerosis an autoimmune disease? APS, CHD, LDL, oxLDL, SLE
81  2016 Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma. aPL, APS
82  2016 Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome. APS
83  2016 Redox Status of beta2GPI in Different Stages of Diabetic Angiopathy. AGEs, CAD, DR, T2DM
84  2016 Soluble analog of ApoER2 targeting beta2-glycoprotein I in immune complexes counteracts hypertension in lupus-prone mice with spontaneous antiphospholipid syndrome. APS
85  2016 The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis. aPL, APS, CL, DI, MS
86  2016 The effect of Toll-like receptor 4 on beta2-glycoprotein I-induced B cell activation in mouse model. APS, BMDCs, TLR4
87  2016 The Fifth Domain of Beta 2 Glycoprotein I Protects from Natural IgM Mediated Cardiac Ischaemia Reperfusion Injury. NAb, WT
88  2016 The Role of TLR4 on B Cell Activation and Anti-beta2GPI Antibody Production in the Antiphospholipid Syndrome. APC, APS, BCR, BMDCs, TLR4
89  2015 beta2-Glycoprotein I-Dependent Anti-Cardiolipin Antibodies Associated With Periodontitis in Patients With Systemic Lupus Erythematosus. anti-CL, SLE
90  2015 Delineating the deranged immune system in the antiphospholipid syndrome. aPL, APS
91  2015 Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. aCL, anti-DI, APS, CLIA, PAPS
92  2015 Determination of clinically significant tests for antiphospholipid antibodies and cutoff levels for obstetric antiphospholipid syndrome. aPL, CL, LA, RPL
93  2015 Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. APS
94  2015 Do Beta 2-Glycoprotein I Disulfide Bonds Protect the Human Retina in the Setting of Age-Related Macular Degeneration? AMD, RPE
95  2015 Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome. APS, CAD, HDs, SLE
96  2015 Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan. Ang, ARBs, BP, HMGB1, oxLDL, TNF-alpha
97  2015 Laboratory methods to detect antiphospholipid antibodies. APS
98  2015 Lipopolysaccharide Enhances Beta2-Glycoprotein I Activation of Nuclear Factor kappaB in Liver Cancer Cells. HBsAg, HCC, LPS, NF-kappaB
99  2015 Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE. aCL, ANAM, aPA, aPC, aPE, aPG, aPI, aPL, aPS, CI, LAC, SLE
100  2015 Oxidatively altered IgG with increased immunoreactivity to beta2-glycoprotein I and its peptide clusters influence human coronary artery endothelial cells. HCAEC, oxIgG